Brief: Pharnext H1 net loss up at 10.1 million euros
Oct 19 (Reuters) - PHARNEXT SAS PHARN.PA :
* H1 NET LOSS EUR 10.1 MILLION VERSUS LOSS OF EUR 8.0
MILLION YEAR AGO
* H1 OPERATING LOSS EUR 9.3 MILLION VERSUS LOSS OF EUR 5.7
MILLION YEAR AGO
* PRO FORMA CASH ASSETS AT END OF JUNE 2017 AFTER TASLY
GROUP'S INVESTMENT, AMOUNT TO EUR 26.1 MILLION
* WE CONFIRM OUR TARGET OF TAKING PRODUCT TO MARKET BY 2019
- CEO
* WE CONFIRM OUR TARGET OF TAKING PRODUCT PXT3003 TO
MARKET BY 2019 - CEO (ADDS DROPPED PRODUCT NAME)
Source text for Eikon: ID:nBw1Ly6DJa
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development